PURPOSE: The aim of the study is to investigate the factors related to coagulation disorders, deep venous thrombosis and thromboembolic events that are important for morbidity and mortality in patients with lung cancer and to detect their relations with prognosis.
METHODS: The patients with lung cancer were included into the study between June 2003 and July 2006 . Laboratory values of patients were detected at the time of diagnosis and coagulation factors were investigated and followed prospectively for any thromboembolic events and survey.
RESULTS: Lactate dehidrogenase (LDH), platelet, D-Dimer (DD), fibrinogen, Von Willebrand factor (vWF) and Prothrombin fragment 1+2 levels were increased in cases with lung cancer and this finding was related with patients’ longevity. Comorbidity, age, histopathological type, stage of the disease, DD, fibrinogen, ECOG, Aspartate transaminase (AST), Alanine transaminase (ALT), LDH, creatinine, sodium, albumine, hemoglobine, vWF, thromboemboli and brain metastasis were the variables which effect the survey. Among these parameters DD, fibrinogen, thromboemboli, ECOG, comorbidity and histopathological type were identified as independent risk factors.
CONCLUSION: The survey was significantly short in cases with detected thromboemboli. Mortality and morbidity may be significantly decreased with early administration of anticoagulant therapy (low molecular weight heparin and warfarin). Anticoagulant therapy can be used in early stage disease with agresive therapies. With administration of anticoagulant therapy, mortality and morbidity may also be decreased in patients with advanced stage disease that have hypercoagulability and/or detected thromboemboli. DD was identified as a cheap and simple test for diagnosis, treatment and follow-up of patients with lung cancer.
CLINICAL IMPLICATIONS: During follow-up period when increased DD levels were detected; patients should be investigated for thromboembolic events.
DISCLOSURE: Arzu Balkan, No Financial Disclosure Information; No Product/Research Disclosure Information